share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K：外国发行人报告
美股sec公告 ·  05/06 17:25
Moomoo AI 已提取核心信息
Cybin Inc., a clinical-stage biopharmaceutical company, announced on May 6, 2024, significant progress in its development pipeline, including a recent U.S. $150 million funding round and the FDA Breakthrough Therapy Designation for its lead program CYB003. CYB003, a deuterated psilocybin analog, is being developed for the adjunctive treatment of Major Depressive Disorder (MDD) and has shown promising Phase 2 results. The company plans to initiate a Phase 3 study for CYB003 in MDD by mid-2024. Additionally, Cybin is advancing CYB004, a deuterated N,N-dimethyltryptamine (DMT) program for Generalized Anxiety Disorder (GAD), with Phase 2 topline efficacy and safety results expected in Q4 2024. Cybin's intellectual property portfolio includes over 50 granted patents and over 170 pending applications, supporting its clinical programs and drug discovery platforms. The company also highlighted its EMBARK training program, designed to prepare facilitators for clinical trials involving psychedelic therapeutics. Cybin's mission is to revolutionize mental healthcare with innovative psychedelic-based treatments.
Cybin Inc., a clinical-stage biopharmaceutical company, announced on May 6, 2024, significant progress in its development pipeline, including a recent U.S. $150 million funding round and the FDA Breakthrough Therapy Designation for its lead program CYB003. CYB003, a deuterated psilocybin analog, is being developed for the adjunctive treatment of Major Depressive Disorder (MDD) and has shown promising Phase 2 results. The company plans to initiate a Phase 3 study for CYB003 in MDD by mid-2024. Additionally, Cybin is advancing CYB004, a deuterated N,N-dimethyltryptamine (DMT) program for Generalized Anxiety Disorder (GAD), with Phase 2 topline efficacy and safety results expected in Q4 2024. Cybin's intellectual property portfolio includes over 50 granted patents and over 170 pending applications, supporting its clinical programs and drug discovery platforms. The company also highlighted its EMBARK training program, designed to prepare facilitators for clinical trials involving psychedelic therapeutics. Cybin's mission is to revolutionize mental healthcare with innovative psychedelic-based treatments.
处于临床阶段的生物制药公司Cybin Inc. 于2024年5月6日宣布其研发计划取得重大进展，包括最近的1.5亿美元融资，以及其主导项目 CYB003 的FDA突破性疗法称号。CYB003 是一种氘代迷幻药类似物，正在开发用于重度抑郁症（MDD）的辅助治疗，并已显示出令人鼓舞的第二阶段结果。该公司计划在 2024 年中期之前启动 MDD 中 CYB003 的三期研究。此外，Cybin正在推进 CYB004，这是一项针对广泛性焦虑症（GAD）的氘化N，N-二甲基色胺（DMT）计划，预计将在2024年第四季度获得第二阶段的疗效和安全性结果。Cybin的知识产权组合包括50多项已授予的专利和170多项待处理的申请，为其临床项目和药物发现平台提供支持。该公司还重点介绍了其EMBARK培训计划，该计划旨在让主持人为涉及迷幻疗法的临床试验做好准备。Cybin的使命是通过基于迷幻药的创新疗法彻底改变心理保健。
处于临床阶段的生物制药公司Cybin Inc. 于2024年5月6日宣布其研发计划取得重大进展，包括最近的1.5亿美元融资，以及其主导项目 CYB003 的FDA突破性疗法称号。CYB003 是一种氘代迷幻药类似物，正在开发用于重度抑郁症（MDD）的辅助治疗，并已显示出令人鼓舞的第二阶段结果。该公司计划在 2024 年中期之前启动 MDD 中 CYB003 的三期研究。此外，Cybin正在推进 CYB004，这是一项针对广泛性焦虑症（GAD）的氘化N，N-二甲基色胺（DMT）计划，预计将在2024年第四季度获得第二阶段的疗效和安全性结果。Cybin的知识产权组合包括50多项已授予的专利和170多项待处理的申请，为其临床项目和药物发现平台提供支持。该公司还重点介绍了其EMBARK培训计划，该计划旨在让主持人为涉及迷幻疗法的临床试验做好准备。Cybin的使命是通过基于迷幻药的创新疗法彻底改变心理保健。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息